Humacyte

HUMA

Market cap $152M

Humacyte, Inc. (HUMA) reached $0.68 at the closing of the latest trading day, reflecting a -7.13% change compared to its last close.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”). On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tiss.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.61, marking a -6.63% move from the previous day.

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.59, representing a -2.44% change from its previous close.

Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.

- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -

- Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.